A diffuse intravascular coagulation (DIC)-like coagulopathy manifesting as prolonged PT and aPTT, hypofibrinogenemia, and thrombocytopenia has been previously reported in patients treated with CD19-targeted CAR-T for RR B-cell acute lymphoblastic leukemia (B-ALL) and large B-cell lymphoma (LBCL) and was shown to correlate with CRS. This evidence concerns the gene CD19 and blood coagulation disease.